Short-Term Debt to Equity Ratio: Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals (MRNS) minimizes capital expenditures by outsourcing drug manufacturing and testing. The current debt-to-equity ratio stands at 0.00, as clearly illustrated in the valuation chart below. Steady demand for its core anti-epileptic product generates consistent revenue, despite the costs associated with its promotion. The business relies on a protected niche of rare diseases, demonstrating complete independence from seasonal factors and market cycles.

This indicator measures the proportion of short-term liabilities relative to equity, allowing for the identification of liquidity risks and cash flow gaps through the history of short-term borrowed capital versus own funds. An increase in this metric signals financial instability, which is critical for Marinus Pharmaceuticals (MRNS), where the need for funds to develop new anti-seizure drugs could intensify pressure on capital.